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Abstract
Human mesenchymal progenitor cells (MPCs) are considered to be of great promise for use in tissue repair and regenerative 
medicine. MPCs represent multipotent adherent cells, able to give rise to multiple mesenchymal lineages such as osteoblasts,
adipocytes or chondrocytes. Recently, we identified and characterized human second trimester amniotic fluid (AF) as a novel source
of MPCs. Herein, we found that early colonies of AF-MPCs consisted of two morphologically distinct adherent cell types, termed as
spindle-shaped (SS) and round-shaped (RS). A detailed analysis of these two populations showed that SS-AF-MPCs expressed CD90
antigen in a higher level and exhibited a greater proliferation and differentiation potential. To characterize better, the molecular identity
of these two populations, we have generated a comparative proteomic map of SS-AF-MPCs and RS-AF-MPCs, identifying 25 differentially
expressed proteins and 10 proteins uniquely expressed in RS-AF-MPCs. Furthermore, SS-AF-MPCs exhibited significantly higher
migration ability on extracellular matrices, such as fibronectin and laminin in vitro, compared to RS-AF-MPCs and thus we further 
evaluated SS-AF-MPCs for potential use as therapeutic tools in vivo. Therefore, we tested whether GFP-lentiviral transduced SS-AF-MPCs
retained their stem cell identity, proliferation and differentiation potential. GFP-SS-AF-MPCs were then successfully delivered into
immunosuppressed mice, distributed in different tissues and survived longterm in vivo. In summary, these results demonstrated that
AF-MPCs consisted of at least two different MPC populations. In addition, SS-AF-MPCs, isolated based on their colony morphology
and CD90 expression, represented the only MPC population that can be expanded easily in culture and used as an efficient tool for
future in vivo therapeutic applications.
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2Introduction
Adult bone marrow (BM) mesenchymal progenitors cells (MPCs) or
mesenchymal stem cells (MSCs), initially described as precursors
of fibroblasts or stromal cells, can be isolated taking advantage of
their adhesive properties and can be further expanded in culture.
Previous studies demonstrated that MPC populations derived
from BM are heterogeneous and contain at least two morphologically
distinct subpopulations of cells: (a) spindle-shaped (SS), rapidly
self-renewing MPCs and (b) flattened-shaped, slowly self-renewing
MPCs [1–4]. More interestingly, this subset of SS MPCs is able to
preferentially engraft in mice; thus, they appear more promising
tools for clinical applications [5]. Similarly, SS and flattened-
shaped MPCs were also isolated from umbilical cord blood (UCB)
at clonal level [6], with SS subpopulation exhibiting high expression
levels of CD90, whereas the flattened was negative for the same
antigen [6].
Recently, our group and others [7–9] have isolated MPCs
from an alternative source, the second trimester amniotic fluid
(AF), which can be obtained during routine amniocentesis 
without any ethical concerns [7, 10–12]. We characterized these
cells based on their phenotype, multipotency, differentiation
potential and on their proteomic profile, constructing a 
two-dimensional electrophoresis (2-DE) proteomic database of
AF-MPCs [7]. Most importantly, AF-MPCs were easily isolated
and grew more rapidly under the appropriate culture conditions
compared to BM-MPCs [7]. In addition, concurrent studies
showed that AF-MPCs, seeded in a scaffold and exposed to
osteogenic-inducing medium, were able to form bone after 
subcutaneous implantation in vivo, demonstrating an important
role in pre-clinical studies [9].
However, AF-MPCs represent a heterogeneous population
composed of multiple categories of adherent cells based on 
morphological, biochemical and growth characteristics [13–16].
Until now, there is no surface epitope or proposed protocol that
can distinguish MPCs in vitro and in vivo [2]. Therefore, most
experiments have been carried out with heterogenous populations
of AF-MPCs [7, 8, 11, 12, 16]. Questions regarding the hetero-
geneity, the mobilization and homing properties of these cells 
in vitro and in vivo, as well as their use as carriers of therapeutic
agents are still undetermined.
Therefore, a large number of parameters must be taken
under consideration in isolating the rapidly expanding MPCs
from AF. First, an important determinant of successful stem cell
therapeutic transplantation is the ability of the transplanted cells
to home, migrate, efficiently engraft and repair damaged tis-
sues. Various molecules have been shown to regulate these
processes in MPCs. Among these are the VLA-5 integrin, which
comprises of 5 (CD49e) and 1 (CD29) subunits and plays key
role in migration [7, 8, 11, 17] and the adhesion molecule CD44,
which is highly expressed in most of the mesenchymal cell
types [18, 19].
Another parameter involves the feasibility of employing genetic
modifications on AF-MPCs by introducing therapeutic genes of
interest. For these manipulations, apart from adenoviruses, that
have been previously utilized in AF-MPCs [20], lentiviral vectors
represent a highly efficient and long-term infection system for
transducing stem cells, without the presence of silencing effects
during multiple divisions [21–23].
Herein, we have extended our previous findings [7], by isolat-
ing and characterizing two different types of AF-MPCs at passage
0 based on their shape, antigen expression levels and functional
properties. We named these cells according to their morphology
as SS and round-shaped (RS) AF-MPCs. SS-AF-MPCs are char-
acterized by a greater proliferation and multilineage differentia-
tion potential, while they are exhibiting higher levels of CD90
compared to RS-AF-MPCs. Therefore, in the current experiments,
we compared their molecular identity, the differentiation capacity
and the in vitro adhesion properties of both subpopulations. We
further analysed the migratory ability, the efficient gene modifica-
tion and the perspective utilization of SS-AF-MPCs in pre-clinical
studies in vivo.
Material and methods
Isolation and culture of MPCs from human AF
Human AF-MPCs were isolated from 95 AF samples, collected during
scheduled amniocentesis between the 15th and 18th week of gestation [7].
Briefly, second trimester AF samples were obtained, following a written
informed consent, approved by the Ethical Committee of the Alexandra
Hospital, Athens and the Bioethics Committee of the University of Athens
School of Medicine, during scheduled amniocenteses between the 15th and
18th week of gestation. Amniocentesis was performed under aseptic con-
ditions. Using a 22G needle and under ultrasonographic control, 10–15 ml
of AF was aspirated for each sample. The procedure-related spontaneous
abortion rate ranges from 0.06% to 0.5% [24, 25]. Samples were collected
and 10 ml of each were centrifuged at 1300 rpm for 10 min. The pellet was
resuspended in Dulbecco’s modified Eagle’s medium (DMEM; Sigma-
Aldrich, St Louis, MO, USA) supplemented with 20% (v/v) foetal bovine
serum (FBS) (Gibco-BRL, Paisley, Scotland, UK), in a 25 cm2 tissue cul-
ture-treated flask and incubated at 37C in a 5% humidified CO2 chamber
for approximately 20 days, where the first colonies appeared. The medium
was then changed every 5 days. The cells were expanded into higher pas-
sages and frozen until use.
Colony forming unit-fibroblast (CFU-F) assay
The CFU-F assay was performed by plating 1  105 AF cells/well into six-
well plates from six randomly selected samples, in the presence of DMEM
(Sigma-Aldrich) supplemented with 20% (v/v) FBS (Gibco-BRL). After
18–20 days of culture, CFUs were formed, mechanically selected and sub-
cultured separately [26]. The cells from each colony were expanded into
higher passages and frozen until use.
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Karyotyping
For karyotyping, RS-AF-MPCs and SS-AF-MPCs from four different sam-
ples each, grown in log phase, were harvested and karyotyped using
Giemsa stain GTG banding, at passage 5. For SS-AF-MPCs, karyotype was
examined at passage 32 as well. Forty metaphase spreads were fully
analysed and karyotyped in each case.
Antibodies and flow cytometry analysis (FACS)
RS-AF-MPCs and SS-AF-MPCs of passage 3–17 were characterized by
FACS analysis using CD90, CD166, CD73, CD105, CD44, c-kit, CD34,
CD133, CD31, CD29, CD49e, CD45, CD50, CD106, CD11a, CD62P, CD1a,
CD13, CD14, CD62E and CD146 [Becton Dickinson (BD), San Jose, CA,
USA], SSEA-4 (Abcam, Cambridge, UK), HLA-ABC and HLA-DR (BD)
mouse anti-human monoclonal antibodies or appropriate isotype controls
(BD). The latter reactions were developed with fluorescein isothiocyanate
(FITC)-conjugated goat anti-mouse IgG secondary antibody (DAKO
DakoCytomation Ltd., Cambridgeshire, UK). For apoptosis detection, cells
were stained with Annexin V-PE (BD) according to manufacturer’s instruc-
tions. Cells were analysed using a Beckman Coulter Cytomics FC 500 flow
cytometer (Beckman Coulter Ltd., Palo Alto, CA, USA). For immunofluores-
cent staining, anti-collagen type I (Sigma-Aldrich), anti-E-cadherin
(Abcam), anti-N-cadherin (Santa Cruz Biotechnology Inc. Santa Cruz, CA,
USA) and anti-Vimentin (Thermo Scientific, Fremont, CA, USA) antibodies
were used in fixed cells with 4% paraformaldehyde (Sigma-Aldrich). The
latter reactions were developed with FITC-conjugated goat anti-mouse IgG
(DAKO DakoCytomation Ltd.) or Alexa-488-conjugated goat anti-rabbit
(Invitrogen Ltd., Paisley, UK) secondary antibodies, where appropriate.
Isotype-matched antibodies were used as negative control. For Oct-4 and
Sox-2 nuclear immunofluorescent staining, cells were permeabilized in
0.2% (v/v) Triton-X (Sigma-Aldrich) for 30 min at room temperature after
fixation as described above. Cells were then stained with rabbit anti-human
Oct-3/4 (Santa Cruz Biotechnology Inc.) or rabbit anti-human Sox-2
(Millipore, CA, USA) antibodies. The latter reactions were developed with
Alexa-488-conjugated goat anti-rabbit (Invitrogen Ltd.) secondary anti-
body. Slides were mounted with Vectashield mounting medium (Vector
Laboratories Inc., CA, USA) containing DAPI solution. Cells were visualized
and photographed on a Leica CTR-MIC Fluorescent microscope.
MTS proliferation assay
MTS assay was performed to estimate the proliferation rate of SS-AF-
MPCs, RS-AF-MPCs or GFP-SS-AF-MPCs. Cells were plated at a density of
103 per well in a 96-well plate and cultured for 6–7 days in the presence of
DMEM (20% FBS) in five replicates. Appropriate amount of MTS (Promega
Ltd, Madison, WI, USA) was added to each well and incubated for 3 hrs.
The absorbance was recorded at 490 nm using an ELISA plate reader (ELX
800; Biotek Instruments Inc, VT, USA). The percentage increase of prolif-
eration was calculated using the following formula: [(ODdayxODday0)/
ODday0  100)]. Statistical analysis was performed using the Student’s 
t-test. Three individual samples from each cell type were analysed.
For conditioned medium (CM) preparation, SS-AF-MPCs were cultured
until 80% confluency and further allowed to grow in a medium containing
20% FBS for 48 hrs. CM was collected, filtered and stored at 20C until
use. RS-AF-MPCs were cultured in CM derived from SS-AF-MPCs for 6 days.
CM was changed every day.
For temperature proliferation analysis, SS-AF-MPCs at passage 15–20
were cultured for 1 and 6 days in DMEM (20% FBS) at 37C and 33C,
respectively.
Transwell migration assay
SS-AF-MPCs (passage 5–15) and RS-AF-MPCs (passage 2–5) were cul-
tured for 48 hrs in DMEM (2% FBS) and then were transferred to the insert
of a 8 mm pore size transwell plate, at 5104/100 	l density (Corning-
Costar, Cambridge, MA, USA). The cells were then allowed to migrate 
for 16 hrs across the pore membrane, towards human plasma fibronectin
(20 	g/ml; Sigma-Aldrich), laminin I (20 	g/ml; Sigma-Aldrich) or DMEM
(2% FBS). The non-migrated cells were removed from the top of the insert
with a cotton swab. The migrated cells were then fixed with 4%
paraformaldehyde (Sigma-Aldrich) on the membrane and stained using the
Ral Kit (Ral Reactif, Paris, France). For migration blocking experiment, cells
were pre-incubated with CD44 (clone 515, BD). Migration was quantified by
counting the stained nuclei that passed through the filter. Photographs
were taken from a minimum of 10 fields of view (20) for each membrane
and then counted by using Image J software. Three independent experi-
ments were performed each including three replicates. Statistical analysis
was performed using the Student’s t-test.
Adhesion assay
SS-AF-MPCs (passage 5–15) and RS-AF-MPCs (passage 2–5) were 
pre-incubated either with CD44 (clone 515, BD), CD49e (blocking antibody,
BD) or IgG1 isotype control (BD) and then transferred to a 24-well plate,
coated with fibronectin (Sigma-Aldrich) or hyaluronic acid (Sigma-Aldrich).
Non-treated SS- and RS-AF-MPCs were used as positive controls. Cells
were let to adhere for 2 hrs and then the supernatant was removed. The
adherent cells to the bottom of the well were fixed with 4% (w/v)
paraformaldehyde (Sigma-Aldrich), stained using the Ral Kit (Ral Reactif).
Photographs were taken from a minimum of 10 fields of view (20) 
for each membrane and then counted by using Image J software. Three
independent experiments were performed, each including three replicates.
Statistical analysis was performed using the Student’s t-test.
RT-PCR procedure
Total RNA was extracted from the cells using the Tri Reagent (Sigma-
Aldrich) according to the manufacturer’s instructions. The mRNA was
reverse transcribed to cDNA using the M-MLV Reverse Transcriptase-
RNase H Minus kit (Promega Ltd.).
Real-time quantitative PCR and semi-quantitative
PCR
Real-time quantitative PCR was conducted on an ABI Prism 7700 apparatus
[Applied Biosystems (ABI), Foster City, CA, USA]. Each cDNA sample was
mixed with specific primer sets and PCR master mix (Applied Biosystems,
No. 4312704). TaqMan RT-PCR was used for oct-4, nanog and sox-2 gene
expression analysis with primers and conditions designated by Assays on
DemandTM, Gene Expression Products [ABI Hs00742896_s1 (oct-4),
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4Hs02387400_s1 (nanog), Hs01053049_s1 9 (sox-2), respectively]. Data
were analysed with the ABI Prism 7700 SDS software (ABI). The expres-
sion of oct-4, nanog and sox-2 was normalized to GAPDH internal control
(GAPDH, ABI, No. 433764T), as described by Zannettino et al. [27]. The
levels of gene expression were normalized after subtracting the Ct value of
the GAPDH internal control from that of the x (x  oct-4, nanog or sox-2)
Ct value for SS-AF-MPCs and RS-AF-MPCs (
Ct  CtX (SS-AF-MPCs or 
RS-AF-MPCs)  Ct GAPDH). To compare the levels of oct-4, nanog and sox-2
expression between SS-AF-MPCs and RS-AF-MPCs, the 

Ct value was
determined using the formula (

Ct  
Ct X(SS-AF-MPCs)  
Ct X(RS-AF-MPCs)).
Then, the relative level of oct-4, nanog and sox-2 in SS-AF-MPCs was com-
pared to RS-AF-MPCs by setting the oct-4, nanog and sox-2 expression in
RS-AF-MPCs value to 1 and determining the fold change in expression
against this value using the following formula: 2

Ct.
PCR reaction for albumin was performed using cDNA, primer pairs and
Go Taq® Green master mix (Promega Ltd.). The primers used were: F: 
5’-AGATGACAACCCAAACCTCCC-3’ and R: 5’-CAGCAGCACGACAGAGTAATC-3’.
The semi-quantitative PCR analysis was determined by using the Image J
software after normalization to the -actin endogenous control (F: 
5’-TCTACAATGAGCTGCGTGTG-3’ and R: 5’-CAACTAAGTCATAGTCCGCC-3’).
Differentiation assays
Osteogenic differentiation
To induce osteogenic differentiation SS-AF-MPCs or RS-AF-MPCs of 
passage 5–7 were cultured to 60–70% confluency in osteogenic medium
for 3 weeks, as described previously [7]. The differentiation potential for
osteogenesis was assessed by alkaline phosphatase staining using BCIP/NBT
reagent (Sigma-Aldrich), according to the manufacturer’s instructions.
Adipogenic differentiation
SS-AF-MPCs or RS-AF-MPCs of passage 5–13, grown as described above,
were treated with adipogenic medium for 3 weeks, as described previously
[7]. Medium changes were carried out twice weekly. For the determination
of adipogenic differentiation, formation of intracellular lipid droplets was
monitored under microscope and was confirmed by Oil Red O staining
(Sigma-Aldrich).
Chondrogenic differentiation
To induce chondrogenic differentiation, SS-AF-MPCs or RS-AF-MPCs of 
passage 5–10, were cultured in high-density pellet mass cultures. Briefly, 
2.5  105 cells were placed into a conical polypropylene tube with 0.5 ml of
defined medium, consisting of DMEM (Sigma-Aldrich) supplemented with
5.33 	g/ml linoleic acid (Sigma-Aldrich), insulintransferrin-selenium
(ITS) (Sigma-Aldrich), 1.25 mg/ml bovine serum albumin (Sigma-Aldrich),
10 ng/ml transforming growth factor 3 (TGF-3) (Peprotech), 107M 
dexamethasone (Sigma-Aldrich), 0.17 mM ascorbate acid (Sigma-Aldrich)
and 0.35 mM L-Proline (Sigma-Aldrich). Cells were centrifuged at 2000 rpm
for 5 min and maintained at 37C for 21 days. Medium was changed twice a
week. After 21 days of pellet mass culture, the pellets were fixed in 10% 
formalin (Sigma-Aldrich), paraffin embedded, sectioned and stained with
Alcian Blue (Sigma-Aldrich) and haematoxylin and eosin (Sigma-Aldrich).
Hepatogenic differentiation
For hepatogenic differentiation, SS-AF-MPCs or RS-AF-MPCs of passage
5–13, at 1.0–1.3  104/cm2 density, were treated with appropriate hepato-
genic medium, as described previously [7]. Hepatogenesis was assessed
after 3 weeks by periodic acid-Schiff (PAS) staining (Sigma-Aldrich),
measurement of urea concentration (Urea UV Liquid, Technologia Diagnostics,
Greece) using the Chemwell 2910 autoanalyzer (Awareness Technology
Inc., Palm City, FL, USA) and determination of albumin expression by
semi-quantitative PCR.
Osteogenic, adipogenic and PAS hepatogenic differentiation assays
were quantified by microscopic analyses of 10 fields per image using the
Image J software.
Proteomic analysis–mass spectrometry (MS)
Three samples of SS- or RS-AF-MPCs of passage 5–10 were analysed by
2D-gel electrophoresis in duplicate each, as described before [7]. Protein
spots were manually excised, tryptic digested and Peptide Mass
Fingerprinted [7]. Stringent criteria were used for protein identification
with a maximum allowed mass error of 25 ppm (parts per million) and a
minimum of five matching peptides [29]. Notably, a high percentage of the
proteins were identified based on 10 matches. The probability of a false
identity was usually lower than 105. All selected proteins were identified
and further analysed for their functional properties by the Swiss-Prot
(http://expasy.org/sprot/) and Human Protein Reference Databases
(http://www.hprd.org/). 2DE image analysis was performed by the use of
the PD-Quest 8.0 (BioRad, Hercules, CA, USA) software package. Protein
expression was shown as a ratio of the intensity of protein spots in SS-AF-
MPCs to RS-AF-MPCs or vice versa in ppm. Comparison of the expression
level of the various protein spots was conducted by the use of Student’s 
t-test and Mann-Whitney test. In all cases, P  0.05 (95% confidence 
levels) was considered statistically significant.
Western blot
Total proteins of SS-AF-MPCs and RS-AF-MPCs were separated by 10%
SDS-PAGE and electroblotted to Hybond-ECL NC membrane (Amersham
Biosciences, Sweden). Protein extracts were derived from a pool of three
SS-AF-MPCs or RS-AF-MPCs individual samples of different passages,
respectively. After blocking, membranes were incubated overnight at 4C
with the primary antibodies: mouse anti-human CK18 (DakoCytomation),
mouse anti-human Cathepsin (BD) or mouse anti-human CK19
(DakoCytomation). Mouse anti-human -actin antibody (Sigma-Aldrich)
was used as a control of equal loading. Membranes were then incubated
with anti-mouse HRP-conjugated secondary antibody (Santa Cruz
Biotechnology Inc.) and developed by ECL (Perkin-Elmer, MA, USA) detec-
tion system. Films were scanned and images were analysed using Quantity
One software (BioRad).
Lentiviral vector generation, production 
and transduction of SS-AF-MPCs
The four plasmid expression lentiviral system containing the
pCCLsin.PPT.hPGK.GFP plasmid [28] was kindly gifted by Prof. L. Naldini
and used for enhanced GFP expression. Virus was produced by transient
transfection into 293T cells, as previously described [29], and collected by
ultracentrifugation using an Ultracentrifuge Discovery 100 Sorvall (Thermo
Fisher Scientific Inc., Waltham, MA, USA). The concentrated virus was
resuspended in PBS supplemented with 0.5% BSA (Sigma-Aldrich). 
The lentiviral titres were determined by infection of HT1080 cells with 
serial dilutions of the concentrated viral stock. GFP fluorescent cells were
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identified by fluorescent microscopy and FACS analysis. Titers ranged from
5  108 to 3  109 infectious units (IU)/ml. Approximately, 5  104 per
well SS-AF-MPCs were seeded in a six-well plate 1 day in advance. Virus
was added in a multiplicity of infection (MOI) of 10–100.
In vivo engraftment of GFP-SS-AF-MPCs
NOD-SCID mice were kindly provided by Drs G. Vassilopoulos and E. Siapati
and were housed and maintained at the Animal Facility of the Biomedical
Research Foundation of the Academy of Athens (BRFAA). The procedures for
the care and treatment of animals were performed according to the institu-
tional guidelines, which follow the guidelines of the Association for
Assessment and Accreditation of Laboratory Animal Care (AAALAC) and the
recommendations of the Federation of European Laboratory Animal Science
Associations (FELASA) and approved by the Institutional (BRFAA) Animal
Care and Use Committee. Six to eight weeks old animals (n  8) received
intravenously (i.v.) by tail vein injection 1  106 GFP-SS-AF-MPCs (passages
15–40). The animals were sacrificed 4 and 10 days later and the tissues were
analysed by immunohistochemistry, FACS and RT-PCR. For the detection of
GFP transgene, genomic DNA was isolated from each organ/tissue collected,
using Proteinase K (Sigma-Aldrich), followed by phenol–chloroform extrac-
tion. RT-PCR analysis was carried out using primers designed on the WPRE
sequence of the lentiviral vector present only in the infused GFP-SS-AF-MPCs
(F: 5’-T T C T C C T C C T T G T A T A A A T C C T G G T T-3’ and R: 5’-C G C
C A C G T T G C C T G A C A-3’) and SYBR master mix (Roche Applied
Sciences, Indianapolis, IN, USA), according to manufacturer’s protocol.
Further, to assess SS-AF-MPCs viability in matrigel in vivo, NOD/SCID
mice of the same age (n  6) received subcutaneously 1106 SS-AF-
MPCs in 200 	l of matrigel (Sigma-Aldrich) into the tail base. As negative
control, 1106 SS-AF-MPCs in 200 	l of PBS were used. The animals
were sacrificed 1 and 10 days later and the matrigel mass was excised and
photographed. Cells were then disassociated by the use of 2% (w/v) colla-
genase (Sigma-Aldrich) for 2 hrs at 37C and analysed by FACS.
Immunohistochemistry
At 4 and 10 days after i.v. injection of GFP-SS-AF-MPCs, animals were sac-
rificed and analysed by immunohistochemistry for GFP or CD90 expres-
sion. Tissues were fixed in 10% formalin (Sigma-Aldrich) and embedded
in paraffin. Non-specific binding was blocked using 10% donkey serum in
PBS. Five-micrometre sections were subsequently incubated with eGFP
(Chemicon, Temecula, CA, USA), CD90 (BD) or appropriate isotype control
antibodies. The reaction was developed with biotinylated goat anti-mouse
secondary antibody (DakoCytomation), followed by ABC-complex-HRP
(DakoCytomation) and DAB (Vector Laboratories Inc.). Slides were coun-
terstained in Gill’s haematoxylin (Sigma-Aldrich).
Results
Phenotypic characterization of two different 
AF-MPC populations
As reported previously, BM-MSC and UCB-MSC cultures contained
distinct cell types differing at shape and size [4, 6]. In this study, cell
pellets from 95 second trimester AF samples were plated according
to previous protocols [7] and then plastic adherent cells were 
isolated. Microscopic analysis led to the identification of two mor-
phological different adherent MPC types in AF, termed as SS (6%,
five established cell lines) and RS MPCs (94%) (Fig. 1A and B). We
initially noticed that the percentage of proliferation increase in SS-AF-
MPCs and RS-AF-MPCs differed during passages 5–7. A more
detailed analysis revealed that SS-AF-MPCs exhibited high prolifera-
tive capacity and were passed over 45 passages to date, whereas
RS-AF-MPCs exhibited a significantly lower proliferative potential
and reached up to passage 4–7 (Fig. 1C). More importantly, RS-AF-
MPCs when cultured in CM derived from SS-AF-MPCs exhibited a
statistically significant increased proliferative potential (Fig. 1C), sug-
gesting that these cells may require paracrine factors derived from
the SS-AF-MPCs for expanding. The identification of these two 
different AF populations is of great importance for potential use of
SS-AF-MPCs in pre-clinical applications and for this reason we
attempted to investigate their characteristics in more detail.
We first observed that unselected cultures at passage 0–1 con-
tained a mixture of SS and RS cells [Fig. 1B(i)]. However, at 
two to three passage in 94% of the sample cases of unselected
cells, the RS cells were more abundant, overtaking the culture
[Fig. 1B(ii)]. The rest 6% of the samples represented a SS cell
population [Fig. 1B(iii)] that can be expanded up to 30–50 pas-
sages to date with normal karyotype [Fig. S1E(i) and (iii)] and high
proliferation capacity (Fig. 1C). The reason why the SS-AF-MPCs
were the predominant and the only population at passages 2–3
onwards in the 6% of the AF samples only, is still undetermined.
In an attempt to characterize better these two subpopulations, we
randomly chose six AF samples at passage 0, where a mixture of
both cell types existed at almost equal frequency. We then
mechanically isolated 20 individual CFUs, 10 with round and 10
with SS morphology in total (Fig. 1A). The clonal SS-AF-MPCs and
RS-AF-MPCs were further expanded in vitro and retained their
morphological characteristics during culture.
The cell surface antigenic characteristics of these two types of
AF-MPCs were examined by FACS analysis. Both types of 
AF-MPCs were negative for CD34, CD133, CD31, CD45, CD14 and
HLA-DR. SS-AF-MPCs and RS-AF-MPCs were positive for MSC
markers CD73, CD105 and CD166, adherent molecules CD29,
CD44, CD49e and HLA-ABC (Fig. 2). The surface marker profiles
were consistent with previously reported BM, AF and UCB hetero-
geneous populations of MSCs [7, 9, 30, 31]. c-kit was expressed
in similar very low/undetectable levels in both SS-AF-MPCs and
RS-AF-MPCs populations, whereas CD146 was expressed in
higher levels in RS-AF-MPCs compared to SS-AF-MPCs (Fig. 2).
However, we observed that SS-AF-MPCs expressed high levels 
of CD90 [median fluorescent intensity (MFI): 58.33  9.68)] 
[Fig. 1B(vi)], whereas RS-AF-MPCs showed lower expression
(MFI: 7.436.53) [Fig. 1B(v)]. We further noticed that unselected
cultures at passage 0 exhibited heterogeneous expression for
CD90, low (MFI 1.6  1.45) and high (MFI 53.4  4.14), which
may indicated the initial co-existence of the two different popula-
tions [Fig. 1B(iv)]. More interestingly, the expression profile of SS-AF-
MPCs and RS-AF-MPCs remained the same during culture, with
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6stable CD90 expression for each population, irrelevant to the cul-
ture passages and to the in vitro MPCs aging (data not shown).
Another important observation was that SS-AF-MPCs exhibited
high expression levels of CD44 adhesion molecule (MFI: 58.95 
8.91) compared to RS-AF-MPCs (MFI: 37.4  10.46). We addi-
tionally examined the expression of MSC markers such as
Vimentin and N-cadherin and also the epithelial marker E-cadherin.
Both cell types were positive for Vimentin, whereas SS-AF-MPCs
expressed E- and N-cadherin in a higher level (Fig. S1A).
CD90 expression altered according 
to the proliferation rate of SS-AF-MPCs
In an attempt to examine a potential relation of the enhanced
expression levels of CD90 in SS-AF-MPCs with the high proliferation
capacity they exhibit, we performed an in vitro proliferation assay
at different temperature culture conditions. It is known from clas-
sical studies that when fibroblast-like cells are cultured at lower
temperature (i.e. 33C), they exhibit a lower proliferation rate [32].
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Fig. 1 Spindle- and round-shaped amniotic
fluid mesenchymal progenitor cells. (A)
Schematic representation of unselected AF-
MPCs and mechanically selected colonies in
an in vitro culture. (B) (i) AF-MPCs colonies
morphology at p0, (ii) RS-AF-MPCs (p5)
and (iii) SS-AF-MPCs (p5) morphology.
Representative FACS histograms of (iv) 
AF-MPCs at p0, gated for CD90 expression
(grey filled histograms), prior to analysis
with the isotype-matched negative control
(open histograms) at p0, (v) homogenous
RS-AF-MPC at p5 and (vi) homogenous 
SS-AF-MPCs at p5 populations, respectively.
(C) Comparative analysis of the percentage
of proliferation of SS-AF-MPCs (blue line),
RS-AF-MPCs (red line) and RS-AF-MPCs
cultured in CM derived from SS-AF-MPCs
(green line), during 6 days of culture by
MTS assay. Values are mean  S.D. for
three independent samples from each MPC
population.
Q1
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Therefore, we performed proliferation analysis assay for SS-AF-
MPCs at 37C (normal temperature conditions) and 33C 
(low temperature conditions), respectively. The proliferation rate
of SS-AF-MPCs dramatically decreased when cultured at 33C for
6 days (Fig. 3A), compared to those cultured at 37C for the same
period. When we examined the expression of mesenchymal-
related antigens at these time points, we observed that CD73 and
CD105 levels were not altered when SS-AF-MPCs were cultured at
33C (Fig. 3B). However, CD90 expression was decreased to
60.08%  26.4 for day 1 [Fig. 3B(i)] and 62.09%  3.65 for day
6 [Fig. 3B(ii)], respectively when the proliferation rate of SS-AF-
MPCs was reduced because of temperature change. These results
showed that CD90 antigen expression might be related to the
growth rate of AF-MPCs and may in turn explain the difference of
proliferation between the SS-AF-MPCs (CD90high) and RS-AF-
MPCs (CD90low) subpopulations.
CD44 neutralizing antibody inhibited SS-AF-MPCs
migration on fibronectin
Initially, a transwell migration assay was developed to determine
the migration potential of SS-AF-MPCs and RS-AF-MPCs to
fibronectin and laminin. Interestingly, SS-AF-MPCs migrated
approximately 7.59- and 7.79-fold faster towards fibronectin and
laminin, respectively, than RS-AF-MPCs [Fig. 4A(i)] (P  0.001,
Student’s t-test).
Taking under consideration that CD44 represented an adhesion
molecule, binding on fibronectin and was expressed in SS-AF-
MPCs in a higher level than RS-AF-MPCs according to FACS
analysis (Fig. 2), we further investigated whether this elevated
expression has a functional role in migration of SS-AF-MPCs. We
therefore performed the same transwell migration assay after 
pre-incubating SS-AF-MPCs with a neutralizing antibody for CD44.
Isotype non-binding antibody (IgG1) was used as a negative 
control. A significant decrease of 31.05%12.13 (P  0.05,
Student’s t-test) in migration capacity of SS-AF-MPCs was
observed in the presence of CD44 blocking antibody [Fig. 4A(ii)].
CD44 neutralizing antibody inhibited SS-AF-MPCs
and RS-AF-MPCs adhesion on fibronectin and
hyalouronic acid
SS-AF-MPCs and RS-AF-MPCs when tested in an in vitro adhesion
assay on fibronectin and hyalouronic acid, exhibited similar 
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Fig. 2 Comparison of SS-AF-
MPCs and RS-AF-MPCs expres-
sion patterns. (A) Representative
FACS histograms of SS-AF-MPCs
(grey filled histograms) and RS-
AF-MPCs (opened histograms)
gated for (i) CD166, (ii) CD73, (iii)
CD146, (iv) CD105, (v) CD44 and
(vi) CD49e markers, prior to analysis
with (vii) the isotype-matched
negative control. (B) SS- and 
RS-AF-MPCs analysed for differ-
ent antigens expression by FACS
analysis. The statistics were made
on the mean MFI for each antigen.
Isotype matched negative controls
were used. Values are shown as
mean  S.D. for three independent
samples from each type. Statistical
analysis was performed using the
Student’s t-test (*P  0.05).
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adhesion capacities on both matrices [Fig. 4B(i–ii)-non-treated
cells]. To analyse in detail the role of CD44 adhesion molecule,
which binds to fibronectin and also to hyalouronic acid [33], we
examined whether CD44 controlled not only the high migration
capacity of SS-AF-MPCs as shown before, but also the adhesion
of both populations to the respective binding matrices. Blocking of
CD44 resulted in lower adhesion of both SS-AF-MPCs and RS-AF-
MPCs on fibronectin at approximately 48% (P  0.05, Student’s
t-test) and 31.3% (P  0.05, Student’s t-test), respectively 
[Fig. 4B(i)]. However, only SS-AF-MPCs exhibited impaired adhe-
sion on hyaluronic acid in the presence of CD44 blocking antibody,
(37.9%, P  0.05, Student’s t-test). There was no significant
effect on cell adhesion using the IgG1 antibody compared to the
non treated cells in both matrices [Fig. 4B(i) and (ii)].
CD49e modulated SS-AF-MPCs and RS-AF-MPCs
adhesion properties
Both cell types express the CD49e molecule which binds to
fibronectin, as determined by FACS analysis (Fig. 2). For examin-
ing the role of CD49e on fibronectin-mediated adhesion, we
analysed SS-AF-MPCs and RS-AF-MPCs in an in vitro adhesion
assay. We observed an approximately 87% (P  0.001, Student’s
t-test) and 68.9% (P  0.001, Student’s t-test) reduction on adhe-
sion ability of SS-AF-MPCs and RS-AF-MPCs, respectively, in the
presence of CD49e blocking antibody, compared to non-treated
cells [Fig. 4B(i)].
SS-AF-MPCs expressed oct-4, nanog and sox-2 
in higher levels than RS-AF-MPCs
We next examined the expression of the oct-4, sox-2 and nanog
transcripts, key markers in embryonic stem cells and responsible
for the maintenance of pluripotency of mammalian stem cells 
in vivo and in vitro, in SS-AF-MPCs and RS-AF-MPCs of passages
5–7 [34, 35]. Oct-4, nanog and sox-2 exhibited a 2.61.38, 
10.41  3.38 and 15.18  3.92 fold higher expression respec-
tively, in SS-AF-MPCs compared to RS-AF-MPCs, by RT-PCR
analysis after normalization to GAPDH endogenous control (Fig. 5A).
However, both AF-MPCs types expressed Oct-4 and Sox-2 at pro-
tein level, as demonstrated by nuclear immunofluorescent staining
(Fig. 5B). In all samples examined, the majority of the cells were
positive for Oct-4 and Sox-2.
SS-AF-MPCs exhibited different differentiation
properties compared to RS-AF-MPCs
SS-AF-MPCs and RS-AF-MPCs were cultured under appropriate
conditions that induce adipocytes, osteocytes, chondrocytes
(mesoderm-derived) and hepatocytes (endoderm-derived), to
evaluate their in vitro differentiation properties (Fig. 6). Results
Fig. 3 CD90 expression alteration according to the proliferation rate of 
SS-AF-MPCs. (A) Comparative analysis of the percentage of proliferation
increase of SS-AF-MPCs at 37C (grey line) and 33C (light grey line),
respectively during 6 days of culture. (B) Comparison of the percentage of
expression of CD73, CD105 and CD90 (i) at day 1 and (ii) day 6 of culture
at 37C (grey bars) and 33C (light grey bars) by FACS analysis, respec-
tively. MFI values were normalized for each marker against the level of
expression determined at 37C, which was set to 100%. Values are shown
as mean  S.D. for three independent experiments. Statistical analysis was
performed using the Student’s t-test (*P  0.05; **P  0.001).
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showed that RS-AF-MPCs exhibited an enhanced adipogenic 
(1.6  0.4 fold times increase) [Fig. 6A (iii)] and reduced
osteogenic (4.6  1.0 fold times decrease) [Fig. 6B(iii)] differen-
tiating capacity compared to SS-AF-MPCs, as determined by oil
red O and alkaline phosphatase staining and quantified by Image
J analysis, respectively. Interestingly enough, under chondrogenic
and hepatogenic inducing conditions, RS-AF-MPCs failed to form
chondrocytes and hepatocyte-like cells respectively, in contrast to
SS-AF-MPCs (Fig. 6C and D). Chondrogenesis, was determined by
Alcian Blue staining of pellets (Fig. 6C). Hepatogenesis was 
verified by PAS staining, where hepatocyte-like cells derived from
SS-AF-MPCs exhibited a 73.07  5.2 fold times increase in PAS
staining compared to SS-AF-MPCs [Fig. 6D(ii)], urea production
(46.5 mg/dl  10.2) compared to SS-AF-MPCs (9.6 mg/dl  6.4)
[Fig. 6D(iii)] and high albumin expression level (12.5  2.4 fold
expression difference compared to SS-AF-MPCs) [Fig. 6D(iv)].
Differentially expressed proteins identified 
in SS-AF-MPCs and RS-AF-MPCs
To further characterize the AF-MPCs subpopulations, proteins 
differentially expressed in SS-AF-MPCs and RS-AF-MPCs were
identified by 2D-gel electrophoreses and MS. Total protein extracts
of three different SS-AF-MPCs and RS-AF-MPCs preparations were
analysed in duplicate by 2DE in 4–7 pH gradient strips. The derived
pattern of resolved protein spots for each cell type was highly con-
sistent and a comparison of the expression levels of the respective
proteins was established using PDQuest 8 software (Fig. 7A and B).
Protein spots that were found to be more than 1.5 times fold differ-
entially expressed and at statistically significant levels (P  0.05
according to Student’s t-test and/or Mann-Whitney test) in the two
subpopulations, are described in detail in Tables S1 and S2.
Specifically, proteins up-regulated in SS-AF-MPCs compared to
RS-AF-MPCs included reticulocalbin-3 precursor, collagen 1 (I)
chain precursor, FK506-binding protein 9 precursor, Rho GDP-
dissociation inhibitor 1, chloride intracellular channel protein 4, 
tryptophanyl-tRNA synthetase and heat shock proteins 1 70 kDa
and 1. On the other hand, proteins such as peroxiredoxin-2, 
60 kDa heat shock protein, glutathione S-transferase P and annexin
A4, were up-regulated in RS-AF-MPCs. Proteins identified only 
in RS-AF-MPCs included cytokeratin 8, 18 and 19, cathepsin B,
coactosin-like protein and integrin -V protein (Table S3).
Among the proteins overexpressed in SS-AF-MPCs, collagen
1 (I), a major extracellular matrix molecule responsible for
directing the fate of MSCs into osteogenic lineages [36], was the
most abundant. This finding may in turn explain the enhanced 
differentiation potential of SS-AF-MPCs to osteoblastic lineages,
as observed in our in vitro studies. Proteins facilitating cell 
migration, such as Rho GDP-dissociation inhibitor 1 [37] and
tryptophanyl-tRNA synthetase [38] are expressed in higher levels
in SS-AF-MPCs, reflecting their enhanced motility in vitro. On the
other hand, the high proliferation rate of SS-AF-MPCs might be
explained by the presence of proteins such as chloride intracellular
channel protein 4, found to promote endothelial cell proliferation
and cell survival [39]. Similarly, heat shock protein 1, exhibiting
Fig. 4 Migration and adhesion properties of
SS-AF-MPCs and RS-AF-MPCs. (A) (i) SS-AF-
MPCs showed higher motility (P  0.001) on
fibronectin and laminin, respectively compared
to RS-AF-MPCs. (ii) Number of migrated SS-
AF-MPCs to fibronectin in presence of CD44
neutralizing antibody or isotype matched non-
specific antibody IgG1. (iii) Representative
image (20) of migrated SS-AF-MPCs fixed
and stained using the Ral staining kit on 
the transwell membrane. (B) (i) Number of
adherent SS-AF-MPCs and RS-AF-MPCs to
fibronectin, treated with CD44, CD49e neutral-
izing antibodies or isotype matched non-
specific antibody IgG1 in comparison to non
treated SS-AF-MPCs and RS-AF-MPCs,
respectively. (ii) Number of adherent SS-AF-
MPCs and RS-AF-MPCs to hyalouronic acid,
treated with CD44 neutralizing antibody or 
isotype matched non-specific antibody IgG1 in
comparison to non treated SS-AF-MPCs and
RS-AF-MPCs, respectively. (iii) Representative
image (20) of adherent cells fixed and stained
using the Ral staining kit on the plastic vessel.
Values are shown as mean  S.D. for three
independent experiments. Statistical analysis
was carried out using the Student’s t-test 
(*P  0.05; **P  0.001).
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an anti-apoptotic role by former studies, was also highly
expressed in SS-AF-MPCs [40, 41].
Confirmation of the differentially expressed proteins
CK18, CK19, cathepsin B and collagen 1 (I)
RS-AF-MPCs exhibited a more complicated protein profile com-
pared to SS-AF-MPCs, including 10 uniquely expressed proteins,
supporting the indication of an earlier developmental stage of the
SS population. To verify the 2DE results and confirm the differen-
tial expression, cytokeratin 18, cytokeratin 19 and cathepsin B
were further analysed by Western blotting. It was demonstrated
that bands of 40, 54 and 28 kDa, corresponding to CK19, CK18
and cathepsin B, respectively were only detected in RS-AF-MPCs
(Fig. 7C). Furthermore, collagen 1 (I) was expressed in higher
levels in SS-AF-MPCs than in RS-AF-MPCs again in agreement to
the 2DE results (Fig. 7D).
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Fig. 5 Embryonic stem cell marker
expression and differentiation potential
of SS-AF-MPCs and RS-AF-MPCs. (A)
Comparative analysis for the expression
of oct-4, nanog and sox-2 in three 
SS-AF-MPCs and RS-AF-MPCs samples,
respectively, analysed by RT-PCR.
Results were first normalized to human
GAPDH positive control and then to 
SS-AF-MPCs expression levels for each
marker, respectively. Statistical analysis
was performed using the Student’s 
t-test. (B) Immunofluorecent nuclear
staining for (i–ii) Oct-4, (iii–iv) Sox-2
and (v–viii) DAPI (ix–xii) of SS-AF-MPCs
and RS- AF-MPCs. Merge of DAPI 
staining and antibody staining. Original
magnifications, 40.
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Lentivirus-mediated gene transfer of AF-MPCs
Taking under consideration the successful, easy and rapid expan-
sion of SS-AF-MPCs in culture, as well as the high passage they
reach compared to RS-AF-MPCs, we further investigated whether
they can be efficiently transduced with lentiviral vectors for further
potential use in in vivo therapeutic applications. For this reason,
SS-AF-MPCs were transduced with GFP third generation lentivirus
[28]. The experimental procedure was focused on three parameters:
first, the efficiency of same passage SS-AF-MPCs transduction by
a virus dose-depended manner; secondly, the efficiency of GFP
expression in different passages and thirdly, the long-term main-
tenance of GFP expression in culture. An increase in fluorescence
of GFP positive SS-AF-MPCs was shown, when the cells, at passage
16, were transduced with rising doses of virus, MOI from 10 to
100, as determined by FACS analysis four days post-transduction
(Fig. 8A and B). The transduction with an MOI of 60 led to a
98–100% efficiency of infection. A very small percentage of cells
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Fig. 6 (A) Oil Red O staining for adipocyte
differentiation for (i) SS-AF-MPCs and (ii)
RS-AF-MPCs respectively, followed by (iii)
quantitation analysis. (B) Alkaline phos-
phatase staining for osteocyte differentiation
for (i) SS-AF-MPCs and (ii) RS-AF-MPCs
respectively, followed by (iii) quantitation
analysis. (C) (i) Alcian Blue and (ii) haema-
toxylin and eosin staining of SS-AF-MPCs,
cultured under chondrogenic inducing 
conditions in pellet mass cultures. (D) PAS
staining for hepatocyte differentiation for 
(i) SS-AF-MPCs induced to hepatocytes. 
(ii) Quantitation analysis for PAS staining,
(iii) determination of the secreted Urea and
(iv) albumin expression were shown.
Quantitation of the respective differentiation
assays was performed by using the Image J
analysis software on 10 fields per image. For
each sample, four images were taken. For
adipogenic and osteogenic differentiation
values were normalized in each case against
the AF-MPC type with the lower differentia-
tion capacity, which was set to 1, whereas
for hepatogenic differentiation, values were
normalized in each case against non-
induced to differentiation SS-AF-MPCs.
Values are mean  S.D. from three samples
from each type. Statistical analysis was per-
formed using the Student’s t-test, P  0.05.
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were positive for Annexin V staining only in virus dosages higher
than MOI 60 (Fig. 8C). The expression levels of mesenchymal
markers (CD90, CD105 and CD73) in SS-AF-MPCs remained the
same after transduction (data not shown).
Furthermore, we performed a different passage expression
analysis using SS-AF-MPCs of passages 10–40, transduced with an
MOI of 60 (Fig. 8D). Interestingly enough, the passage did not affect
the expression of GFP. In addition, the expression of GFP was main-
tained at the same high levels 4 weeks and 9 months post-transduction
(Fig. 8E). By series of freezing and thawing cycles we observed that
the expression of GFP remained constant. In addition, GFP-SS-AF-
MPCs (MOI 60) exhibited high proliferation capacity (Fig. S1B) and
were still capable to differentiate into adipogenic, osteogenic and
hepatogenic lineages in vitro, as shown in Figure S1C.
In vivo engraftment of left ventricular transduced
SS-AF-MPCs
The high proliferation rate of SS-AF-MPCs and the fact that they
exhibit normal karyotype at high passages, allowed the use of
these cells in vivo. RS-AF-MPCs were not efficient in number to be
used in in vivo experiments.
Thus, we further investigated the in vivo survival, migration
and engraftment of GFP-SS-AF-MPCs in non-damaged immuno-
supressed mice. GFP-SS-AF-MPCs were i.v. injected into
NOD/SCID mice and then analyses involving FACS, immunohisto-
chemistry and RT-PCR for the WPRE gene were used, to follow
the distribution of donor cells 4 and 10 days post-injection at dif-
ferent tissues (Fig. 9). For immunohistochemistry anti-human
CD90 antibody, which does not cross-react with mouse MSCs and
tissue (Fig. S1D) was also used. We were able to detect GFP-SS-
AF-MPCs at liver, spleen, lung, gut and kidney at these time points.
However, similarly to previous studies with MSCs [42], we could
not detect SS-AF-MPCs in the BM as confirmed by FACS analysis
(data not shown). No tumours were detected even after 3 months
post-SS-AF-MPCs transplantation in NOD/SCID animals, which
may indicate non-tumorigenic properties of these cells.
Furthermore, we tested the viability of SS-AF-MPCs supported
by matrigel and transplanted subcutaneously into the tail bases of
NOD/SCID mice. It was demonstrated by fluorescent microscopy
and FACS analyses that matrigel succeeded in supporting SS-AF-
MPCs engraftment for at least 10 days without losing the GFP
expression (Fig. 9D). This finding proved that extracellular compo-
nents provided by matrigel were needed to improve SS-AF-MPCs
survival and engraftment in vivo.
Discussion
Recent interest is focused on AF as a valuable source of 
MPCs [7–9, 11, 12]. Culture of AF-MPCs, as previously reported
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Fig. 7 Two-dimensional gel electrophoretic
analysis of AF-MPCs. (A) Representative
2D-gel electrophoresis image of proteins
extracted from SS-AF-MPCs and (B) 
RS-AF-MPCs. The differentially and unique
expressed protein spots in each population
are indicated with their abbreviated names
and listed in Tables S1–3, respectively. (C)
Confirmation of the cytoskeratin 19 and 18
and cathepsin B expression by Western blot
analysis with the respective antibodies in
cell extracts from SS-AF-MPCs (lanes 1)
and RS-AF-MPCs (lanes 2). Protein bands of
40, 54 and 38 kDa corresponding to
cytoskeratin 19 and 18 and cathepsin B
heavy chain were detected. Immunoblotting
for b-actin has been conducted to ensure the
comparable loading of proteins in each lane.
(D) Confirmation of the higher expression of
collagen 1 (I) protein in SS-AF-MPCs 
compared to RS-AF-MPCs by immunofluo-
rescent staining.
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Fig. 8 Transduction of SS-AF-MPCs with the pCCLsin.PPT.hPGK.GFP lentiviral system. (A) Flow cytometric analysis, (B) microscopic evaluation (20)
and (C) evaluation of apoptosis by Annexin V staining by FACS analysis of SS-AF-MPCs at MOI 5–100 and passage 16 (D) GFP efficiency of SS-AF-MPCs
determined 4 days post-transduction at passages 10, 20, 30 and 40 by FACS analysis of MOI 60. (E) Stability of GFP expression 1 and 9 months post-
transduction by FACS analysis at MOI 60.
Fig. 9 In vivo engraftment of GFP transduced SS-AF-MPCs. (A) GFP-SS-AF-MPCs were trapped in different tissues as evaluated by immunohistochem-
istry, 4 and 10 days after transplantation. GFP-SS-AF-MPCs were found in liver, spleen, lung and kidney at low frequency. Immunohistochemistry was
performed by using anti-GFP antibody. Quantitation of GFP cells was determined by (B) FACS analysis and (C) RT-PCR in the respective tissues 4 or 
10 days post-injection where percentage of positive cells and GFP fold expression difference is presented, respectively. As negative controls, non-injected
mice were used. Values are shown as mean  S.D. for four mice in each group. (D) (i) Representative post-mortem fluorescent microscopy image of SS-
AF-MPCs within the matrigel revealed a robust engraftment. (ii) FACS analysis of the disassociated matrigel area in presence of GFP transduced SS-AF-
MPCs (red filled histogram) or GFP transduced SS-AF-MPCs in PBS (open histogram) 1 and 10 days post-transplantation.
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from our group and others, yielded in an adherent heterogenic
cell population with diverse morphology [7, 8, 11]. The
expression analysis, determined by FACS analysis, documented
the presence of CD44, CD90, CD73 and CD105 and the 
absence of haematopoietic-related CD-antigens [7, 8, 11],
resembling to the phenotype of MSC-like cells according to
standard criteria [43].
In our previous studies, we successfully isolated and expanded
karyotypically normal MSCs from 80 samples of second trimester
AF and performed a systematic phenotypic, molecular and pro-
teomic analysis [7]. The main characteristic of the AF-MSCs was
the high number of isolated cells and their rapid expansion in vitro
compared to BM-MSCs. More importantly, these cells when
exposed to appropriate differentiation media in vitro, showed a
multilineage differentiation potential and ability to overcome the
mesodermal commitment, by differentiating into cell types derived
from all three germ layers [7].
In this study, we focused on the detailed investigation of differ-
ent populations of AF-MPCs. We initially observed that unselected
cultures contained, at passage 0–1, two morphologically distinct
populations, SS-AF-MPCs and RS-AF-MPCs, whereas at passage
2–3 the RS cells were more abundant in 94% of the samples. The
rest 6% of the samples represented a SS cell population that can
be expanded up to 40–50 passages to date. In an attempt to char-
acterize better these two subpopulations, we randomly chose six
AF samples at passage 0, where a mixture of both cell types
existed at almost equal frequency, then we mechanically isolated
SS or RS colonies and successfully expanded them under the
same culture conditions.
Although cultures of MPCs have been studied extensively the
last decades, standard criteria for isolating and expanding these
cells have not been developed [4]. Several protocols have been
established for isolating human MPCs from different sources by
using staining with different antibodies [3, 4, 6–9, 11, 13, 16, 44].
Other groups have reported that the existence of morphologically
distinct MPC subpopulations is related to the plating density of the
sample [1, 4, 44]. However, in this study, we observed the pres-
ence of both RS-AF-MPCs and SS-AF-MPCs at passage 0 despite
the initial plating density.
A detailed examination of the phenotype of SS-AF-MPCs and
RS-AF-MPCs showed that SS-AF-MPCs expressed higher levels 
of CD90. However, the unselected AF-MPCs cultures at passage
0–1 exhibited a mixed expression of CD90 revealing the initial co-
existence of both SS and RS cells. This observation was consistent
with older reports on murine lung fibroblasts and UCB-MPCs, in
which two morphologically different populations were identified,
one SS and CD90 positive, and the other one rounded and CD90
negative. Furthermore, it has been shown that CD90 expression
affected the morphology, proliferation and differentiation of fibrob-
lasts [45]. RS-AF-MPCs shared similar morphological characteris-
tics to human amniotic membrane epithelial cells (hAEC), which
express stem cell markers and have the ability to differentiate to
multiple cell lineages [46]. However, hAEC differentiate success-
fully to hepatocytes and exhibit increased expression of CD90 after
second passage in culture, in contrast to RS-AF-MPCs [46]. 
In addition, SS-AF-MPCs shared the rapid expansion and the
multi-lineage differentiation potential of human umbilical cord
perivascular cells (HUCPVCs), whereas they exhibited low expres-
sion of CD146, a marker characteristic for circulating endothelial
cells [47].
We further decided to study in more detail the molecular
identity and specific properties of the SS-AF-MPC population.
We observed that CD90 expression was decreased when the
proliferation rate of SS-AF-MPCs was reduced because of tem-
perature change. These results showed that CD90 antigen
expression could be related to the growth rate of AF-MPCs and
may in turn explain the difference of proliferation between 
SS-AF-MPCs (CD90high) and RS-AF-MPCs (CD90low) subpopula-
tions. However, temperature change may also affect other
biological parameters and for this reason further investigation is
needed to explore the signaling pathway that is possibly related
to this observation.
Furthermore, despite the similar stem cell features of SS-AF-
MPCs and RS-AF-MPCs, the first ones possess a significantly
higher migration capacity, compared to RS-AF-MPCs. This find-
ing provided a basis for a more extended investigation of the
migration mechanism of SS-AF-MPCs, involving a variety of
adhesion molecules such as VLA-4, VLA-5, CD29 or CD44 [48].
For example, blocking studies by using CD44 neutralizing
antibody showed impaired migration properties of SS-AF-MPCs
on fibronectin.
SS-AF-MPCs and RS-AF-MPCs expressed the pluripotency
markers Oct-4 and Sox-2, indicating a possible primitive pheno-
type and stem cell potential of these cells. Similar findings by
Guillot et al. [7, 49] for MSCs isolated from first-trimester foetal
blood, liver and BM confirmed that MSCs derived from neonatal
and mid-gestational foetal tissues also expressed pluripotency
markers, such as Oct-4 and Sox-2. In parallel, comparative
studies by Greco et al. [50], showed that MSCs and embryonic
stem cells (ESCs) shared similar expression of the embryonic
transcription factors Oct-4, Sox-2 and Nanog, both at RNA and
protein levels.
In addition, by the use of proteomic analysis, 25 proteins were
found differentially expressed among the two subpopulations,
which might explain the discrepancy in their proliferation, migration
and differentiation properties. The differentially expressed proteins
between SS-AF-MPCs and RS-AF-MPCs did not include any of the
proteins highly expressed in MSCs from various sources such as
Vimentin, Galectin, Gelsolin and Prohibitin [7, 47].
Our data indicated for the first time that SS-AF-MPCs are
highly susceptible to lentiviral transduction, with no silencing
effects over the multiple culture passaging. Moreover, GFP
expression was retained through in vitro differentiation of SS-
AF-MPCs, indicating the prospective utilization of this type of
MPCs in gene therapy applications. Previous studies showed
that human AF stem cells, seeded in a scaffold and exposed to
osteogenic-inducing medium, can form bone in vivo [9].
However, up to date there have been no conclusive reports
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demonstrating the in vivo contribution of AF-MPCs upon
intravenous delivery without tissue damage of the recipient
animals. Here, we report that the SS-AF-MPCs can home into
several tissues, at low frequency, after systemic infusion into
recipient animals and can be tracked in lung, liver or spleen after
several days. More importantly, we have demonstrated that
matrigel supported SS-AF-MPCs engraftment is superior to cells
alone. This can be explained by the specific properties of the
matrigel basement, providing growth factors and structural
support to the cells [6, 45, 51–53].
Therefore, we succeeded in mechanically isolating and
expanding two mesenchymal origin populations of AF (SS-AF-
MPCs and RS-AF-MPCs) that co-exist at early passage. SS-AF-
MPCs are characterized by higher CD90 antigen expression
than RS-AF-MPCs. The ease with which SS-AF-MPCs can be
expanded in culture represents a marked contrast to the diffi-
culties that have been encountered in expanding MPCs derived
from sources such as BM, AF or UCB [6, 7, 9, 11, 31]. The
specific properties of SS-AF-MPCs related to migration ability,
differentiation capacity, lentiviral transduction efficiency and
long-term survival in vivo will be of great importance in their
use for cell and gene therapy. Under the conditions developed
in this study, from a 10 ml AF sample we can mechanically 
isolate SS-AF-MPCs colonies that can generate millions of cells
in culture in a short period of time, enough for future clinical
applications.
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